000			05581cam a2200445Ii 4500
001			95780
003			ES-MaUEC
005			20230102112721.0
006			m o d
007			cr cnu---unuuu
008			170411s2017 sz ob 001 0 eng d
020			_a3319468774 _q(electronic bk.)
020			_a9783319468778 _q(electronic bk.)
020			_z3319468758
020			_z9783319468754
040			_aN$T _cN$T _dN$T _dEBLCP _dGW5XE _dYDX _dOCLCF _dUAB _dOCLCO _dMERER _dESU _dAZU _dUPM _dOCLCO _dIOG _dOCLCO _dVT2 _dOTZ _dOCLCQ _dOCLCO _dJG0 _dOCLCO _dOCLCA _dU3W _dOCLCO _dES-MaUEC _bspa
050		4	_aRS431.A64 _b2017 EB
245	0	0	_aNext generation antibody drug conjugates (ADCs) and immunotoxins _cUlf Grawunder, Stefan Barth, editors.
264		1	_aCham _bSpringer _c2017.
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	0		_aMilestones in drug therapy
500			_aSpringerLink _bSpringer Biomedical and Life Sciences eBooks 2017 English+International
504			_aIncluye referencias bibliográficas e índice
505	0		_aPreface; The Complexity of ADCs and ITs; Contents; Chapter 1: Chemical Assembly of Antibody-Drug Conjugates; 1.1 Introduction; 1.2 Conjugation via Natural Amino Acid Residues; 1.2.1 Random Conjugation at Native Cysteine Residues; 1.2.2 Site-Specific Conjugation at Engineered Cysteine Residues; 1.2.3 Stabilization of Maleimide Linkage; 1.2.4 Hydrophilic Spacers; 1.2.5 Cysteine-Bridged Conjugation; 1.2.6 Site-Specific Conjugation at Engineered Selenocysteine Residues; 1.2.7 Random Conjugation at Native Lysine Residues; 1.2.7.1 Maytansinoid ADCs; 1.2.7.2 Calicheamicin ADCs.
505	8		_a1.3 Conjugation via Unnatural Amino Acids1.3.1 Site-Specific Conjugation at Engineered p-Acetyl-Phe Residues; 1.3.2 Site-Specific Conjugation at Engineered p-Azidomethyl-Phe Residues; 1.3.3 Site-Specific Conjugation at Engineered Formylglycine Residues; 1.4 Conclusions; References; Chapter 2: Preclinical Evaluation of ADCs Delivering Highly Potent Pyrrolobenzodiazepine (PBD) Dimers; 2.1 Background to the PBDs; 2.2 Antibody PBD Conjugates (APCs); 2.2.1 C2-Linked APCs; 2.2.2 N10-Linked APCs; 2.3 Emerging Clinical Data; 2.4 Properties and Advantages of APCs; 2.5 Conclusions; References.
505	8		_a4.2 Preclinical Activities of Inotuzumab Ozogamicin4.3 Preclinical and Clinical Experience with Gemtuzumab Ozogamicin; 4.4 Ephrin-A4 (EFNA4): A Novel Target for Calicheamicin Conjugates; 4.5 Antitumor Activity of the EFNA4-ADC Against CSCs in Triple Negative Breast Cancer (TNBC) and Ovarian Carcinomas (OVCA)PDX ... ; 4.6 Conclusions and Future Perspectives; References; Chapter 5: Enzyme-Based Strategies to Generate Site-Specifically Conjugated Antibody Drug Conjugates; 5.1 Introduction; 5.2 Enzymatic Conjugation Technologies Used for the Generation of Site-Specifically Conjugated ADCs.
505	8		_a5.2.1 Strategies Involving Bacterial Transglutaminase (BTG) Enzyme5.2.2 Use of Sortase Enzymes for Generating Homogeneous ADCs; 5.2.3 Formyl-glycine Converting Enzyme (FGE) Approach; 5.2.4 Split Inteins for Generating Site-Specifically Conjugated ADCs; 5.2.5 Glycan-Remodeling Approaches to Create Handles for Site-Specific Conjugation; 5.2.6 Other Enzymatic Approaches; 5.3 Conclusions; References; Chapter 6: Substance P-Saporin for the Treatment of Intractable Pain; 6.1 Introduction; 6.2 Animal and Human Tests of SP-SAP; 6.2.1 The Substance-P and Saporin Molecules.
505	8		_aChapter 3: Stable and Homogeneous Drug Conjugation by Sequential Bis-Alkylation at Disulphide Bonds Using Bis-Sulphone Reagents3.1 Introduction; 3.2 Bis-Sulphone Reagents for Disulphide Bridging Conjugation; 3.3 Reagent; 3.4 ADC Characterisation; 3.4.1 ADC Stability; 3.5 In Vitro Potency; 3.6 In Vivo Efficacy; 3.7 Antibody Fragments; 3.8 Fab Drug Conjugates; 3.9 Imaging Applications; 3.10 Conclusion; References; Chapter 4: Calicheamicin Antibody-Drug Conjugates for Liquid and Solid Tumor Indications; 4.1 Mechanism of Action of Calicheamicin as an ADC Payload.
520	3		_aThis book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities. The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology.
650		7	_aToxinas _2embne _0(OCoLC)fst00810456 _0 _9146398
700	1		_aBarth, Stefan, _eeditor literario
700	1		_aGrawunder, Ulf, _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-46877-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aEBOOK, asignarmaterias, EBSPRINGER_2017C
998			_b02/2018 _dz _e- _zSI
999			_c95780 _d95780 _x1